Emerging evidence from genomics, post-mortem, and preclinical studies point to a potential
dysregulation of molecular signaling at postsynaptic density (PSD) in schizophrenia …

This review summarizes the current state of knowledge regarding the proposed mechanisms
by which antipsychotic agents reduce the symptoms of schizophrenia while giving rise to …

The neurotransmitter dopamine (DA) plays a central role in the control of motor function,
emotional states, and endocrine physiology. The discovery that schizophrenic symptoms …

Schizophrenia is a common and devastating illness. The cause of schizophrenia is still
unknown and the simplest formulation of the “Dopamine hypothesis” posits that …

The effects of new generation antipsychotic drugs (APDs) targeting dopamine D2 and
serotonin 5-HT1A receptors were compared with typical and atypical APDs on …

Multiple lines of evidence including recent imaging studies suggest that schizophrenia is
associated with an imbalance of the dopaminergic system, entailing hyperstimulation of …

Introduction: For over half a century now, the dopamine hypothesis has provided the most
widely accepted heuristic model linking pathophysiology and treatment in schizophrenia …

The first part of the present review describes the exciting journey of dopamine stabilizers,
starting in the early eighties with the development of the partial dopamine agonist (-)-3-PPP …

With the introduction of conventional antipsychotics in the 1950s, clinicians began to expect
effective treatment of positive symptoms of schizophrenia. However, these drugs do not …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …